S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%
A daily business newspaper · Founded in 2026

Money Talk

Finance and markets: business, quotes, gold, energy and releases.

Zillow Faces Securities Class Action Over Redfin Antitrust Allegations

A federal class action lawsuit now targets Zillow Group and its senior executives, accusing the company of securities fraud. Filed in the U.S. District Court for the Western District of Washington, the complaint alleges that Zillow misled investors regarding the true nature of its rental listings agreement with Redfin.

Zillow Faces Securities Class Action Over Redfin Antitrust Allegations
Photo: Bio & News

The legal action, captioned Breidert v. Zillow Group, Inc., et al., claims that Zillow paid Redfin $100 million in 2025 as part of an anticompetitive pact to exit the multifamily rental advertising market and stifle competition. While Zillow initially framed the deal as a strategic partnership, the Federal Trade Commission later challenged the arrangement as an illegal attempt to bypass fair market competition.

Investors have seen significant volatility linked to the ongoing legal scrutiny. On February 11, 2026, shares experienced a sharp decline—dropping 16.54% for Class C and 17.13% for Class A stock—after the company’s CFO disclosed that mounting legal expenses would create a 200-basis-point headwind to EBITDA margins. This followed earlier market reactions to the FTC’s initial complaint and a subsequent federal judge’s refusal to dismiss the case. The law firm Bleichmar Fonti & Auld LLP is representing the class, with a lead plaintiff deadline set for August 10, 2026.

Share article
TelegramXFacebook

When reusing this material a link to Money Talk is required.

Comments (0)

Leave a comment

No comments yet. Be the first!